Flex­ion se­cures Chi­na deal for os­teoarthri­tis drug; Strug­gling to find a buy­er, Ako­rn throws in the tow­el

→ Flex­ion may be hit­ting the brakes on clin­i­cal tri­als, in­clud­ing one for its os­teoarthri­tis drug Zil­ret­ta, but that’s not stop­ping the biotech from plot­ting reg­u­la­to­ry ac­tion in Chi­na. Hong Kong Tain­uo has com­mit­ted $10 mil­lion up­front to seize the de­vel­op­ment and com­mer­cial­iza­tion rights to Zil­ret­ta, with plans to ap­ply for a clin­i­cal tri­al in Chi­na by the end of the year. Flex­ion, which said it has 10 months of fin­ished goods in the US and 12 months of ac­tive phar­ma­ceu­ti­cal in­gre­di­ent avail­able, will sup­ply all prod­ucts to the Chi­nese part­ner.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER